JP Morgan Maintains Neutral on Zimmer Biomet Holdings, Lowers Price Target to $95

Benzinga Newsdesk www.benzinga.com Neutral 55.0%

Neg 0% Neu 55% Pos 0%

JP Morgan analyst Robbie Marcus maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Neutral and lowers the price target from $100 to $95.